SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx

Sun Yat-sen University

Status and phase: Enrolling; Phase 2

Conditions: Laryngeal Cancer; Hypopharynx Cancer

Treatments: Combination Product: SBRT+Toripalimab Plus Docetaxel and Cisplatin

Study type: Interventional

Funder types: Other

Identifiers

NCT06611137

B2024-373-01

Details and patient eligibility

About

This trial aims to evaluate the safety and efficiency of SBRT followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx

Enrollment: 35 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Laryngeal (T3-4N0-3M0 ) and hypopharyngeal ( T2-4N0-3M0) cancers staged by AJCC8th
• age 18-70
• PS score 0-1
• normal functions to tolerate chemotherapy, immunotherapy and radiotherapy

Exclusion criteria

• Patients with a combination of other malignant tumours
• Individuals with contraindications to immunotherapy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

35 participants in 1 patient group

SBRT+Toripalimab Plus Docetaxel and Cisplatin

Experimental group

Description:

SBRT for gross tumor and metastatic lymph nodes, followed by neoadjuvant chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin

Treatment:

Combination Product: SBRT+Toripalimab Plus Docetaxel and Cisplatin